345627-80-7 | Sns-032

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$21.00	$15.00
5mg	98%	in stock	$60.00	$42.00
10mg	98%	in stock	$86.00	$60.00
25mg	98%	in stock	$149.00	$104.00
50mg	98%	in stock	$180.00	$126.00
100mg	98%	in stock	$299.00	$209.00
250mg	98%	in stock	$611.00	$428.00
1g	98%	in stock	$1,538.00	$1,077.00
5g	98%	in stock	$4,611.00	$3,228.00

Description

• Catalog Number: AF68085
• Chemical Name: Sns-032
• CAS Number: 345627-80-7
• Molecular Formula: C17H24N4O2S2
• Molecular Weight: 380.5281
• MDL Number: MFCD09833875
• SMILES: O=C(C1CCNCC1)Nc1ncc(s1)SCc1ncc(o1)C(C)(C)C

Computed Properties

• Complexity: 454
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 25
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 6
• XLogP3: 3

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.

  Journal of medicinal chemistry 20130214

• Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120401

• Comprehensive analysis of kinase inhibitor selectivity.

  Nature biotechnology 20111030

• Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.

  European journal of medicinal chemistry 20110601

• The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.

  Leukemia 20110301

• Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.

  Blood 20110106

• Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells.

  Leukemia 20110101

• Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

  Chemistry & biology 20101124

• Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.

  Cancer research 20100815

• Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100620

• The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells.

  Lung cancer (Amsterdam, Netherlands) 20091001

• SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.

  Cancer chemotherapy and pharmacology 20090901

• Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032.

  Cancer prevention research (Philadelphia, Pa.) 20090901

• Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.

  Blood 20090507

• SNS-032 prevents hypoxia-mediated glioblastoma cell invasion by inhibiting hypoxia inducible factor-1alpha expression.

  International journal of oncology 20090401

• Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked.

  Cell cycle (Georgetown, Tex.) 20081215

• Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio.

  Bioorganic & medicinal chemistry letters 20081201

• A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties.

  Bioorganic & medicinal chemistry letters 20081101

• A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.

  Investigational new drugs 20080201

• A quantitative analysis of kinase inhibitor selectivity.

  Nature biotechnology 20080101

• Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity.

  Oncogene 20070524

• SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor.

  Neoplasia (New York, N.Y.) 20070501

• The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1beta-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells.

  Cancer research 20060201

• Drugging cell cycle kinases in cancer therapy.

  Current drug targets 20050501

• P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats.

  Cancer chemotherapy and pharmacology 20050201

• E2F4 deficiency promotes drug-induced apoptosis.

  Cancer biology & therapy 20041201

• N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent.

  Journal of medicinal chemistry 20040325